QQQ   307.86 (+1.41%)
AAPL   154.30 (+1.69%)
MSFT   267.90 (+4.33%)
META   190.98 (+2.64%)
GOOGL   107.11 (+4.09%)
AMZN   101.71 (-0.46%)
TSLA   195.34 (+0.30%)
NVDA   221.06 (+4.82%)
NIO   10.85 (-0.73%)
BABA   105.39 (-0.06%)
AMD   85.71 (+2.43%)
T   19.28 (-1.53%)
F   13.42 (+2.13%)
MU   61.92 (+3.23%)
CGC   2.81 (-4.75%)
GE   81.80 (-0.67%)
DIS   111.48 (+1.47%)
AMC   6.12 (-10.00%)
PFE   43.56 (-0.46%)
PYPL   83.07 (+0.90%)
NFLX   361.42 (-0.02%)
QQQ   307.86 (+1.41%)
AAPL   154.30 (+1.69%)
MSFT   267.90 (+4.33%)
META   190.98 (+2.64%)
GOOGL   107.11 (+4.09%)
AMZN   101.71 (-0.46%)
TSLA   195.34 (+0.30%)
NVDA   221.06 (+4.82%)
NIO   10.85 (-0.73%)
BABA   105.39 (-0.06%)
AMD   85.71 (+2.43%)
T   19.28 (-1.53%)
F   13.42 (+2.13%)
MU   61.92 (+3.23%)
CGC   2.81 (-4.75%)
GE   81.80 (-0.67%)
DIS   111.48 (+1.47%)
AMC   6.12 (-10.00%)
PFE   43.56 (-0.46%)
PYPL   83.07 (+0.90%)
NFLX   361.42 (-0.02%)
QQQ   307.86 (+1.41%)
AAPL   154.30 (+1.69%)
MSFT   267.90 (+4.33%)
META   190.98 (+2.64%)
GOOGL   107.11 (+4.09%)
AMZN   101.71 (-0.46%)
TSLA   195.34 (+0.30%)
NVDA   221.06 (+4.82%)
NIO   10.85 (-0.73%)
BABA   105.39 (-0.06%)
AMD   85.71 (+2.43%)
T   19.28 (-1.53%)
F   13.42 (+2.13%)
MU   61.92 (+3.23%)
CGC   2.81 (-4.75%)
GE   81.80 (-0.67%)
DIS   111.48 (+1.47%)
AMC   6.12 (-10.00%)
PFE   43.56 (-0.46%)
PYPL   83.07 (+0.90%)
NFLX   361.42 (-0.02%)
QQQ   307.86 (+1.41%)
AAPL   154.30 (+1.69%)
MSFT   267.90 (+4.33%)
META   190.98 (+2.64%)
GOOGL   107.11 (+4.09%)
AMZN   101.71 (-0.46%)
TSLA   195.34 (+0.30%)
NVDA   221.06 (+4.82%)
NIO   10.85 (-0.73%)
BABA   105.39 (-0.06%)
AMD   85.71 (+2.43%)
T   19.28 (-1.53%)
F   13.42 (+2.13%)
MU   61.92 (+3.23%)
CGC   2.81 (-4.75%)
GE   81.80 (-0.67%)
DIS   111.48 (+1.47%)
AMC   6.12 (-10.00%)
PFE   43.56 (-0.46%)
PYPL   83.07 (+0.90%)
NFLX   361.42 (-0.02%)
NASDAQ:VKTX

Viking Therapeutics - VKTX Stock Forecast, Price & News

$9.83
+0.27 (+2.82%)
(As of 02/7/2023 03:41 PM ET)
Add
Compare
Today's Range
$9.37
$9.85
50-Day Range
$3.55
$9.56
52-Week Range
$2.02
$9.85
Volume
1.41 million shs
Average Volume
1.69 million shs
Market Capitalization
$753.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.75

Viking Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
33.0% Upside
$12.75 Price Target
Short Interest
Bearish
8.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.96mentions of Viking Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.88) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

573rd out of 1,029 stocks

Pharmaceutical Preparations Industry

276th out of 504 stocks

VKTX stock logo

About Viking Therapeutics (NASDAQ:VKTX) Stock

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Stock News Headlines

Viking Therapeutics's Earnings: A Preview
GRAPHITE: "Essential for America's National Defense"
Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider.
Viking Therapeutics (VKTX) to Release Earnings on Wednesday
Viking Therapeutics (NASDAQ:VKTX) Shares Down 3.5%
VKTX.OQ - | Stock Price & Latest News | Reuters
GRAPHITE: "Essential for America's National Defense"
Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider.
VKTX Viking Therapeutics, Inc.
SVB Securities Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Recap: Viking Therapeutics Q3 Earnings
Earnings Outlook For Viking Therapeutics
SVB Securities Keeps Their Buy Rating on Viking Therapeutics (VKTX)
Viking Therapeutics: Playing Second Fiddle To Madrigal
See More Headlines
Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Company Calendar

Last Earnings
11/03/2021
Today
2/07/2023
Next Earnings (Confirmed)
2/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VKTX
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.75
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+29.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-54,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.58 per share

Miscellaneous

Free Float
72,470,000
Market Cap
$753.86 million
Optionable
Optionable
Beta
0.77

Key Executives

  • Brian Lian
    President, Chief Executive Officer & Director
  • Marianne Mancini
    Chief Operating Officer
  • Gregory S. Zante
    Chief Financial Officer
  • Michael Morneau
    Vice President-Finance & Administration













VKTX Stock - Frequently Asked Questions

Should I buy or sell Viking Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings
or view top-rated stocks.

What is Viking Therapeutics' stock price forecast for 2023?

2 brokerages have issued 1 year target prices for Viking Therapeutics' shares. Their VKTX share price forecasts range from $10.00 to $15.00. On average, they anticipate the company's stock price to reach $12.75 in the next year. This suggests a possible upside of 33.4% from the stock's current price.
View analysts price targets for VKTX
or view top-rated stocks among Wall Street analysts.

How have VKTX shares performed in 2023?

Viking Therapeutics' stock was trading at $9.40 at the beginning of the year. Since then, VKTX shares have increased by 1.7% and is now trading at $9.56.
View the best growth stocks for 2023 here
.

When is Viking Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our VKTX earnings forecast
.

How can I listen to Viking Therapeutics' earnings call?

Viking Therapeutics will be holding an earnings conference call on Wednesday, February 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "8094886".

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. During the same quarter in the prior year, the firm posted ($0.13) earnings per share.

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Moody Aldrich Partners LLC (0.26%), Simplex Trading LLC (0.00%), Quantum Private Wealth LLC (0.08%), Titleist Asset Management LTD. (0.02%), Forum Financial Management LP (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of Viking Therapeutics?

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $9.56.

How much money does Viking Therapeutics make?

Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $733.16 million. The biotechnology company earns $-54,990,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com.

This page (NASDAQ:VKTX) was last updated on 2/7/2023 by MarketBeat.com Staff